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We have previously described the human homolog
of a rat metastasis-associated molecule, hC4.4 A,
with a weak homology to the urokinase-type plasmi-
nogen activator receptor. By the restricted expres-
sion in nontransformed tissues as opposed to
expression in roughly 50% of a variety of carcinoma
lines of different origins, a possible correlation
between hC4.4 A and tumor progression emerged.
This was explored in more detail in melanoma by
quantitative polymerase chain reaction and in situ
hybridization. As shown before, normal human skin
weakly expresses hC4.4A. Melanocytes and nevi are
negative, but up to 60% of primary malignant mela-
noma and 100% of lymph node and skin metastases
of melanoma are hC4.4A positive. Signal intensity in
both polymerase chain reaction and in situ hybridiza-
tion varied considerably between individual samples,
which is indicative for regulated expression of
hC4.4 A. To test the hypothesis, melanoma lines
were incubated with human serum. Whereas expres-
sion of hC4.4 was not in¯uenced by heat-inactivated
human serum, all melanoma lines responded to non-
inactivated human serum with upregulation of
hC4.4 A expression. Regulated expression with high-
est level expression on metastases is a feature that
hC4.4 A shares with the urokinase-type plasminogen
activator receptor. This feature points towards func-
tional activity of hC4.4 A in tumor progression. Key
words: metastasis marker/uPAR. J Invest Dermatol
116:344±347, 2001
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atrix-degrading enzymes and their receptors are
important for tumor invasion and metastasis
formation (Kim et al, 1998; Ohtani, 1998). The
association with the metastatic phenotype mainly
relies on overexpression and/or altered func-
tional activity of the receptors (Liotta and Stetler-Stevenson, 1990;
Kwaan, 1992; Bode et al, 1999; Curran and Murray, 1999), i.e.,
most of the matrix-degrading enzymes only become activated by
binding to their speci®c receptor or they are protected from
degradation in the receptor-bound state (Cubellis et al, 1989;
Burgle et al, 1997; Nagase, 1997; Price et al, 1997; Yu et al, 1997).
The receptors themselves may have additional functions. This has
been most convincingly demonstrated for the phosphatidyl inositol
anchored urokinase-type plasminogen activator receptor (uPAR),
which is involved also in cell migration and signal transduction
(Andreasen et al, 1997; Blasi, 1997; Plesner et al, 1997; Reuning
et al, 1998; Shetty and Idell, 1998; Wang et al, 1998; Kitajima et al,
1999; Nguyen et al, 1999; Wie et al, 1999).
We recently cloned a rat gene, C4.4 A, and its human homolog,
hC4.4 A (RoÈsel et al, 1998; WuÈrfel et al, in press), which has a low
degree of homology to uPAR. Whereas most GPI-anchored
molecules have only one extracellular domain, C4.4 A, like uPAR,
has three extracellular domains, the homologies between the two
molecules being restricted to the two N-terminal domains (Ploug
et al, 1991; RoÈsel et al, 1998). As revealed by transfection of C4.4 A
cDNA in a nonmetastasizing tumor line, the molecule facilitates
invasion by degradation of the extracellular matrix, although
expression of C4.4 A by itself is not suf®cient for matrigel
penetration. C4.4 A cDNA transfected tumor cells also display an
aggressive metastasizing phenotype with degradation of vessel walls
and bronchiolar epithelium and no encapsulation of primary and
metastatic nodules (RoÈsel et al, 1998). Different to the uPAR
(Kristensen, 1992), expression of rat and human C4.4 A on
nontransformed cells is rare, i.e., restricted to the basal layer of
the epidermis, the epithelial layers of the esophagus and the uterine
gland, some monocytes, and placental tissue (RoÈsel et al, 1998;
WuÈrfel et al, in press). In the rat, expression on transformed cells is
strictly correlated to the metastatic phenotype (Claas et al, 1996).
When analyzing human tumor lines, about 50% of carcinoma lines
of different origin expressed hC4.4 A. Furthermore, preliminary
evidence pointed towards upregulation on metastatic tissue. Thus,
we speculated that hC4.4 A may provide a new diagnostic marker
for tumor progression and that expression may be regulated
according to the functional activity of the tumor cell. We were able
to support the hypotheses by an analysis of primary tumors and
metastases of melanoma as well as by varying the culture conditions
of melanoma lines.
MATERIALS AND METHODS
Human tissue and cell lines Shock-frozen normal human tissue of
seven nevi (®ve congenital and two dermal nevi), 10 primary malignant
melanoma (®ve super®cial spreading melanoma, four nodular melanoma,
one acrolentiginous melanoma) of different thicknesses according to the
Breslow de®nition, eight lymph node metastases, and seven skin metastases
were collected at the Department of Dermatology, University of the
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Saarland, Homburg, Saar. Patients' consent had been obtained in all cases.
Cultured melanocytes were obtained from PromoCell, Heidelberg,
Germany, and were cultured as recommended for four to six passages.
The melanoma lines BS1251, Colo38, W+, and MML1 were obtained
from the American Type Culture Collection or were established at the
Department. With the exception of MML1, these lines were derived from
metastatic tissue.
Treatment of melanoma lines For the evaluation of activation-
dependent expression of hC4.4 A, melanoma lines were starved overnight
in RPMI 1640 medium not containing fetal bovine serum. Thereafter they
were cultured for 24 h in medium containing 10% heat-inactivated fetal
bovine serum or 10% AB0 serum that was or was not heat-inactivated for
30 min at 56°C.
RNA in situ hybridization (ISH) In order to generate a human
C4.4 A-speci®c RNA probe we ®rst performed reverse transcriptase
polymerase chain reaction (RT-PCR) with 5 mg RNA using the following
primers: 5¢-GCCCCAGCAGCCCCATAATAAA (hC4.4 A 1037±1058)
and 5¢-CACCCACCCCACGCTCCAAAGT (hC4.4 A 1483±1504). The
resulting DNA product of 467 bp was gel-eluted and puri®ed using the
Qiaquick Gel Extraction Kit (Qiagen, Hilden, Germany) and subsequently
cloned into the pCRII-Topo vector (Invitrogen, Groningen, The
Netherlands). After sequence analysis, sense and antisense probes were
generated by in vitro transcription using T7 or Sp6 RNA polymerase. The
probe was digoxigenin (DIG)-labeled using the Boehringer RNA DIG-
labeling Kit (Roche, Mannheim, Germany). Cryosections (6 mm) or
cytospins (105 cells) were ®xed in 4% paraformaldehyde for 1 h and
pretreated with 1 mg per ml pepsin in 0.1 M HCl for 5 min and with 0.1 M
triethanolamine/0.25 M acetic acid anhydride for 10 min. Sections or
cytospins were hybridized overnight with 400 ng per ml DIG-labeled sense
or antisense hC4.4 A probe at 55°C. Subsequently, sections were incubated
with an anti-DIG alkaline phosphatase monoclonal antibody (Roche) for
2 h at room temperature. After an overnight incubation with nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Roche), sections
were counterstained with methylgreen (Vector Laboratories, Burlingame,
CA) and embedded in Kaiser's glycerin (Merck, Darmstadt, Germany).
RT-PCR mRNA was isolated with the Oligotex mRNA puri®cation
system (Quiagen) using the manufacturer's protocol. cDNA was
synthesized using 1 mg of polyA+ RNA, MuMLV reverse transcriptase,
and oligo dT. First-strand cDNA was subjected to RT-PCR ampli®cation.
Using polyA+ RNA-derived cDNA the following human C4.4 A-speci®c
oligonucleotides were used for the ampli®cation (32 cycles at 55°C): GCC
CCA GCA GCC CCA TAA TAA A and CAC CCA CCC CAC GCT
CCA AAG T. Ampli®cation of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (oligonucleotides: GGT CGG AGT CAA
CGG ATT TG and ATG AGC CCC AGC CTT CTC CAT) was
Table I. mRNA expression of hC4.4A: RT-PCR vs ISH
Tissue RT-PCR ISH
skin weak signal stratum basale (weak)
freshly cultured melanocytes negative negative
nevi negative (7/7) negative (7/7)
primary melanoma positive (7/10) positive (10/10)
weak ® strong few ® most cells
skin metastases positive (7/7) positive (7/7)
medium ® strong most cells
lymph node metastases positive (8/8) positive (8/8)
mostly strong most ® all cells
Figure 1. Expression of hC4.4 A on melanocytes and melanoma. Sections (5 mm) of shock-frozen tissue from normal human skin (a, b), a primary
melanoma (c, d), a skin metastasis (e, f), and a lymph node metastasis (g, h) were hybridized with DIG-labeled sense (a, c, e, g) and antisense (b, d, f, h) hC4.4 A
probes. In (i) (sense) and (j) (antisense) a primary culture of keratinocytes was hybridized. Hybridization was visualized by anti-DIG alkaline phosphatase
staining and substrate treatment. Sections were counterstained with methylgreen. Scale bar: 1 mm.
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performed for 35 cycles at 60°C. The C4.4 A-speci®c and the GAPDH-
speci®c primers amplify a PCR fragment of 460 bp and 400 bp,
respectively. RT-PCR products were analyzed on 1% agarose gels
stained with ethidium bromide. In real-time PCR, 2 ml of cDNA was
added to 18 ml PCR mix (LightCycler Fast Start DNA Master SYBR
Green I kit, Roche Diagnostics). SYBR Green intercalates between
double-stranded DNA and a ¯uorescence signal is generated through a laser
beam. Fluorescence emission is measured and continuously monitored
during PCR. The ¯uorescence signal is plotted versus cross-points that mark
the cycle number when ¯uorescence becomes signi®cantly different from
baseline signal.
RESULTS AND DISCUSSION
Expression of hC4.4A on melanocytes and melanoma
Expression of hC4.4 A was evaluated by RT-PCR and ISH in
melanocytes, unaltered skin, seven nevi, 10 primary melanoma,
eight lymph node metastases, and seven skin metastases of
melanoma (Table I and Fig 1). As shown before (WuÈrfel et al, in
press), human skin weakly expressed hC4.4 A, the expression being
restricted to the suprabasal cell layer. Furthermore, C4.4 A was
highly expressed by some, though not all, cells in primary cultures
of human keratinocytes. Neither melanocytes nor nevi expressed
hC4.4 A. With primary melanoma the picture was not uniform. By
RT-PCR, no signal was obtained with three out of 10 tumors,
weak signals were seen with ®ve, and strong signals with two
samples. All skin and lymph node metastases expressed hC4.4 A, the
signals being in most instances stronger than those of primary
tumors. Similar ®ndings were found with ISH. In primary
melanoma at least some cells were positive in all 10 tumors. A
higher percentage of cells, though not all, were stained in sections
of skin metastases. In lymph node metastases, the vast majority of
tumor cells expressed hC4.4 A mRNA.
These ®ndings exclude that hC4.4 A is a differentiation marker
of cells of the melanocytic lineage. Furthermore, hC4.4 A is not
expressed constitutively on melanoma cells, but its expression
appears to be upregulated during tumor progression.
Activational state dependent expression of hC4.4A Because
of the higher expression level of hC4.4 on metastases of melanoma,
it became tempting to speculate that the activational state of tumor
cells may have a bearing on hC4.4 A expression. To support the
assumption (Table II), melanoma cell lines were starved overnight,
i.e., were cultured in the absence of fetal bovine serum. Thereafter
they were cultured in the presence of human serum that had not
been heat inactivated, and expression of hC4.4 A was evaluated by
quantitative PCR. Transcription of hC4.4 A became upregulated
by all four tested lines, the increase spanning a range from 2.3- to
8.2-fold. Importantly, when the cells were cultured in the presence
of heat-inactivated human serum, no such increase was observed,
i.e., expression was in the same range or below the one of cells
cultured in the presence of heat-inactivated fetal bovine serum.
Expression of rat C4.4 A facilitates matrix degradation and
interferes with adhesion to laminin (RoÈsel et al, 1998). The ®nding
that expression of hC4.4 A is upregulated on metastasizing
melanoma cells could well be in line with functional activity of
hC4.4 A in matrix degradation and is reminiscent of uPAR
expression on colon carcinoma, which correlates with the
metastastic capacity (Ploug and Ellis, 1994). Activation of
transcription is another phenomenon shared with the uPAR gene,
transcription of which has been described to be regulated by nerve
growth factor, epidermal growth factor, serum factors VII and VIIa,
as well as by transforming growth factor b1 (Lund et al, 1995;
Taniguchi et al, 1998; Ghiso et al, 1999; Farias-Eisner et al, 2000).
Work is in progress to identify the heat-labile serum factor(s)
responsible for the transcriptional regulation of hC4.4 A. Our data
indicate a very restricted expression in nontransformed cells and a
high expression on metastases. Thus, hC4.4 A will possibly be
important as a prognostic indicator and a therapeutic target.
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